Portfolio Lab

Eton Pharmaceuticals, Inc.

  • Stock
  • Ticker ETON
  • Nasdaq

Health care · Pharmaceuticals · USA

$60.85 −0.83%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Eton Pharmaceuticals, Inc. since 11/2018, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

ETONGlobal equities (VT)

$10,000 grew to $105,642. Global equities (VT): $14,653.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −79.9% in 10/2022, measured from the peak in 02/2021. It took 45 months to get back to the old peak.

1-year return
+273.3%
5-year return p.a.
+67.9%
Return p.a. since 11/2018
+32.8%
Volatility p.a.
63.9%
Largest decline
−79.9%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue1217192221243858
Gross profit6.59.9127.913152544
Operating income0.6-0.5-1.5-1.42.52.41323
EBITDA1.00.5-0.5-1.43.53.51423
Net income-0.6-1.6-2.6-1.91.51.61235
Earnings per share-0.03-0.06-0.10-0.070.060.050.351.06
Balance sheet
Total assets76841021059298116157
Liabilities5260788166676970
Equity2424242326314787
Cash1517253726202756
Long-term debt3030272822191911
Cash flow
Operating cash flow-0.82.18.012-127.47.335
Capital expenditure0.00.00.0-0.30.0-0.10.00.0
Free cash flow-0.82.18.012-127.37.335

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2024 at +204.1%, weakest 2021 at −47.2%. 5 of 7 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
5 Nov 2026$1.06
13 Aug 2026$0.35
14 May 2026$0.05
19 Mar 2026$0.06
6 Nov 2025−$0.07
7 Aug 2025−$0.10
13 May 2025−$0.06
18 Mar 2025−$0.03
12 Nov 2024$0.02
8 Aug 2024−$0.12
9 May 2024−$0.03
14 Mar 2024−$0.09

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€1.6bn
Market cap in trading currency
$1.76bn
Enterprise value
$1.72bn
P/E
40.0
P/S
12.44
P/B
20.19
EV/Sales
12.21
EV/EBITDA
38.9
Earnings yield
2.5%
FCF yield
2.2%

Results (last four quarters)

Revenue
$141m
Gross profit
$97.5m
EBITDA
$44.2m
Net income
$49.9m
Earnings per share
$1.52
Revenue per share
$4.89
Revenue growth
+157.9%
Earnings growth
–

Profitability

Gross margin
69.2%
Operating margin
28.8%
Net margin
35.3%
Return on equity
90.6%
Return on assets
31.7%

Balance sheet and cash flow

Cash
$55.6m
Cash per share
$1.93
Financial debt
$23.1m
Debt/equity %
27
Current ratio
1.79
Book value per share
$3.01
Operating cash flow
$38.4m
Free cash flow
$38.2m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
28.8m
Volume
529,649
Avg. volume 3 months
581,344
Relative volume
0.9

Price and technicals

Price
$60.85
1 day
−0.8%
52-week high
$68.40
52-week low
$14.35
Distance to 52-week high
−11.0%
Distance to 52-week low
+324.0%
Distance to 50-day line
+9.3%
Distance to 200-day line
+55.9%
RSI (14)
55
Volatility 1M
95.8%

Performance

1 week
−4.8%
1 month
+21.7%
3 months
−5.6%
6 months
+86.7%
YTD
+259.8%
1 year
+261.8%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has ETON performed since 11/2018?

$10,000 grew to $97,360 by 20 Nov 2026, which is +32.8% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is ETON?

Volatility was 63.9% per year, measured on monthly returns. The largest decline from a peak was −79.9%, with the low in 10/2022.

How does ETON compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.4% per year at 16.3% volatility, ETON returned +32.8% at 63.9%. The correlation of monthly returns was 0.24; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Eton Pharmaceuticals, Inc. (ETON): Return and risk